Diabetic Ketoacidosis Treatment Market Insights by Growth, Emerging Trends and Forecast by 2032

The technological developments in diabetic ketoacidosis treatment, substantial prevalence of target diseases is projected to boost the global diabetic ketoacidosis treatment market growth. The factors such as important side effects of the prevailing diabetic ketoacidosis drugs, shortage of skilled clinicians and inadequate facilities in less established or low income nations, and strict government regulations for drug development are anticipated to constrain the market growth during the forecasted period.

The occurrence of diabetes continued stable at 30 cases per 100,000 children every year during the forecasted period. Age- and gender-standardized rates of diabetic ketoacidosis augmented from 22% (95% confidence interval [CI] 17% -26%) in 2001 to 30% (95% CI 24% -36%) in 2014. The relative upsurge the incidence of diabetic ketoacidosis in the identification of diabetes during the study period was 2.0% each year. Growing awareness among healthcare specialists about ketones build up during type 1 diabetes as well as type 2 diabetes, and favourable funding scenario for drug development and technological advancements in diabetes ketoacidosis treatment is predicted to boost the growth of the market during the forecast period. Ketoacidosis, hyperglycaemia and ketonuria during diabetic ketoacidosis makes it a critical life threatening disorder of diabetes. Also, growing prevalence of type 1 diabetes around the globe, growing availability of well-organized and technically advanced diabetic ketoacidosis treatment in emerging nations, substantial R&D activities by the present and developing market players to make effective drugs in an attempt to fulfil the demand supply gap in the market.

The beginning of COVID-19 has impacted financial status of numerous industry verticals across the global. The private healthcare sector is among the sectors, which has been significantly obstructed by the global pandemic. Furthermore, the pandemic has impacted growth of several businesses owing to safety measures instigated by many governments globally. The epidemic has affected the economy in three main ways, such as by creating disturbances in supply channels, by directly distressing production and demand, and through its monetary impact on healthcare markets around the world. As a result, the pandemic is anticipated to obstruct the global diabetic ketoacidosis treatment market growth during the forecasted period.

Treatment Insights
Based on the treatment, the global diabetic ketoacidosis treatment market is bifurcated into fluid replacement, electrolyte replacement, insulin therapy, intermediate-acting insulin, and long-acting insulin. The insulin therapy segment is anticipated to register significant revenue growth during the forecasted period. Factors such as growing incidence of diabetes and diabetic ketoacidosis across the globe, high preference for insulin therapy owing to its cost-effectiveness and high efficacy, and rapid developments in insulin therapy are estimated to fuel revenue growth of the segment.

Region Insights
North America is anticipated to register largest revenue share owing to growing prevalence of diabetes and related complications such as diabetic ketoacidosis around the region, existence of well-developed healthcare structure and research amenities, and availability of cutting-edge treatment for diabetic ketoacidosis. Additionally, existence of prominent market players, high awareness of early diagnosis and treatment, and beneficial reimbursement situations are anticipated to drive revenue growth of the market in the region.

The diabetic ketoacidosis medication market in Asia Pacific is anticipated to register highest CAGR over the forecasted period. The augmented prevalence of type 1 diabetes and the extensive implementation of sedentary lifestyles are anticipated to boost revenue growth of the market. Other important factors that are estimated to endorse revenue growth are ageing population and augmented acceptance of fruitful methods by top companies situated in China and India. Additional factor that is estimated to drive revenue growth of the market in the region is increasing use of insulin therapy, which is supported by ongoing developments in the field of insulin delivery method.

Key Companies Insights
The market for diabetic ketoacidosis treatment is moderately competitive. With the rising applications of diabetic ketoacidosis treatment, new players are considering to enter the market. The companies are also involved in events like joint ventures, partnerships, acquisitions, mergers, and collaborations. These activities aid in growing the effect of the players in the diabetic ketoacidosis treatment market, ultimately boosting the market growth.

Some of the key companies working in the global diabetic ketoacidosis treatment market include:
• Novo Nordisk
• Sanofi S.A.
• Biocon
• Tonghua Dongbao Pharmaceutical Co., Ltd
• The Bristol-Myers Squibb Company
• GSK plc
• Merck & Co
• Pfizer Inc.
• Oramed Pharmaceuticals
• Eli Lilly and Company
• Other players

Some of the Recent Developments:
• In October 2021, Cipla and Eli Lilly and Company (India) broadcasted a strategic partnership in India. Eli Lilly will hand over its rights to promote, sell, and distribute Humalog and Trulicity in India to Cipla as part of the contract, subject to all regulatory approvals. The aim of this collaboration is to upsurge access to Lilly’s key diabetic medications in the nation.
• In July 2021, Eli Lily and Company declared the acquisition of Protomer Technologies Inc. This acquisition will benefit Eli Lily to focus on progressing glucose-responsive insulins.
• In August 2020, Eli Lilly and Company added two unbranded insulin products Humalog mix 75/25 kwikpen and Humalog Junior kwikpen in a cost-effective line to enhance the management of type 1 diabetes and its obstacles such than diabetic ketoacidosis at an inexpensive price.

Segments
By Treatment
• Fluid Replacement
• Electrolyte Replacement
• Insulin Therapy
• Intermediate-Acting Insulin
• Long-Acting Insulin 

By Route of Administration
• Oral
• Parenteral
• Others

By Distribution Channel
• Online Channel
• Offline Channel

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt